Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.
Atara Biotherapeutics traded up $0.10, hitting $39.70, during trading hours on Thursday, Marketbeat reports. The company’s stock had a trading volume of 345,041 shares, compared to its average volume of 490,755. The firm has a market capitalization of $1.74 billion, a PE ratio of -9.93 and a beta of 2.55. Atara Biotherapeutics has a 52-week low of $39.60 and a 52-week high of $41.55.
Get Atara Biotherapeutics alerts:
In other Atara Biotherapeutics news, CFO John Mcgrath sold 13,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $47.07, for a total value of $611,910.00. Following the completion of the transaction, the chief financial officer now owns 99,056 shares in the company, valued at $4,662,565.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 8,800 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $37.44, for a total transaction of $329,472.00. Following the completion of the transaction, the chief executive officer now owns 808,675 shares of the company’s stock, valued at approximately $30,276,792. The disclosure for this sale can be found here. Insiders sold 186,168 shares of company stock worth $7,952,433 in the last three months. 10.60% of the stock is currently owned by corporate insiders.
Several research firms recently commented on ATRA. ValuEngine raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “sell” rating in a report on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $70.00 target price on shares of Atara Biotherapeutics in a report on Tuesday. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Tuesday, March 20th. Finally, BidaskClub lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 4th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $42.50.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.